No price history available.
Key financial summary
Financials in INR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | INRm | 9,343 | 12,020 | 14,349 | 13,113 | 12,486 | 14,173 | 15,950 | N/A | N/A |
| Operating profit | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | INRm | 977 | 1,542 | 1,891 | 1,044 | 349 | 31 | -764 | N/A | N/A |
| EPS reported | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in INR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Value | ||||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | ||||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | ||||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | ||||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Heranba Industries Limited, headquartered in Mumbai, India, specializes in the manufacturing, marketing, and sale of a comprehensive range of agrochemicals. The company's extensive product portfolio includes essential intermediate chemicals (e.g., cypermethric acid chloride, high CIS CMA and CMAC, high trans CMA and CMAC, bromobenzenes, metaphenoxy benzaldehyde and benzyl alcohol, and NPBR) and a wide array of technical-grade active ingredients (such as cypermethrin, deltamethrin, alpha cypermethrin, acephate, lambda cyhalothrin, bifenthrin, tranfluthrin, tricyclazole, hexaconazole, tebuconazole, glyphosate, metribuzin, clodinafop, and bispyribac sodium). Additionally, Heranba provides diverse pesticide formulations, including emulsifiable concentrate, water dispersible granule, suspension concentrate, capsule suspension, oil dispersion, concentrated aqueous emulsions, suspoemulsion, and ZC formulation. These products collectively address various pest control needs, covering insecticides, herbicides, fungicides, and public health applications. Beyond its strong domestic presence within India, the company also boasts an international footprint, exporting its products to approximately 65 countries worldwide. Established in 1992, the company was initially known as Heranba Industrial Chemicals Limited before adopting its current name, Heranba Industries Limited, in July 1996.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Heranba Industries Limited (HERANBA.NS)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Heranba Industries Limited, headquartered in Mumbai, India, specializes in the manufacturing, marketing, and sale of a comprehensive range of agrochemicals. The company's extensive product portfolio includes essential intermediate chemicals (e.g., cypermethric acid chloride, high CIS CMA and CMAC, high trans CMA and CMAC, bromobenzenes, metaphenoxy benzaldehyde and benzyl alcohol, and NPBR) and a wide array of technical-grade active ingredients (such as cypermethrin, deltamethrin, alpha cypermethrin, acephate, lambda cyhalothrin, bifenthrin, tranfluthrin, tricyclazole, hexaconazole, tebuconazole, glyphosate, metribuzin, clodinafop, and bispyribac sodium). Additionally, Heranba provides diverse pesticide formulations, including emulsifiable concentrate, water dispersible granule, suspension concentrate, capsule suspension, oil dispersion, concentrated aqueous emulsions, suspoemulsion, and ZC formulation. These products collectively address various pest control needs, covering insecticides, herbicides, fungicides, and public health applications. Beyond its strong domestic presence within India, the company also boasts an international footprint, exporting its products to approximately 65 countries worldwide. Established in 1992, the company was initially known as Heranba Industrial Chemicals Limited before adopting its current name, Heranba Industries Limited, in July 1996.